Our study found that the TMEM44-AS1-IGF2BP2-GPX4 axis is involved in the pathogenesis and progression of ESCC, providing new diagnostic biomarkers and therapeutic targets for ESCC patients. This evidence concerns the gene TMEM44 and esophageal squamous cell carcinoma.